Vidyya Medical News Service
*
Volume 5 Issue 194 Published - 14:00 UTC 08:00 EST 13-July-2003 Next Update - 14:00 UTC 08:00 EST 14-July-2003
little clear gif used for spacer
.
*

The it-can't-happen-here response to bioterrorism
A study by researchers at Saint Louis University School of Public Health found that while a majority of health care professionals surveyed believe the United States is at a high or somewhat high risk of bioterrorism (74 percent), the same professionals believe that their individual communities are at low risk of an attack (32 percent).  more

*
Higher education or larger brain size may protect against dementia later in life, new study finds
Higher education or a larger brain may protect against dementia, according to new findings by researchers from the University of South Florida and the University of Kentucky. more

 


*
A Novel, Bone-targeted mTOR Inhibitor that Decreases Both Tumor Proliferation and Bone Breakdown for the Treatment of Bone Cancer (Abstract 717)
A new bone-targeted rapamycin analog, AP23841, is designed to inhibit primary bone cancer tumor growth and halt the growth of bone metastases, according to researchers at ARIAD Pharmaceuticals, Inc., Massachusetts. Rapamycin is an immunosuppressant indicated to prevent organ rejection.  more

*
Efficacy of Radioimmunotherapy with Radiolabeled HerceptinTM in Combination with Gemcitabine in the Treatment of Intraperitoneal Disease (Abstract 5787)
Treatment regimens combining chemotherapeutics and radioimmunotherapy may have tremendous potential in the management and treatment of cancer patients, according to a study presented by researchers from the National Cancer Institute. HER2, a member of the epidermal growth factor receptor family, is a promising target for radioimmunotherapy, (RIT) a therapy that uses antibodies as vehicles to direct radiation to tumor cells. more

*
MAC-321: A Novel Taxane with Greater Efficacy than Paclitaxel and Docetaxel In Vitro and In Vivo (Abstract 5779)
A novel taxane inhibits the growth of paclitaxel and docetaxel-resistant tumor cell lines, according to data presented by scientists at Wyeth Research, Pearl River, NY. Both paclitaxel and docetaxel are widely used for the treatment of lung, breast and ovarian cancers, but many tumor types eventually become resistant to the drugs.  more

 
little clear gif used for a space